TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease.
This study reports a 1-year-old boy with precursor B cell acute lymphoblastic leukemia (ALL) carrying t(16;21)(p11;q22). Reverse transcriptase-polymerase chain reaction (RT-PCR) and direct sequence analysis showed TLS/FUS-ERG chimeric mRNA with a novel junctional pattern of exon 7 of TLS/FUS and exon 6 of ERG. He did not respond to ALL-oriented therapy. Complete remission (CR) was achieved by chemotherapy oriented for acute myeloid leukemia. Allogenic bone marrow transplantation was done and he has been in CR for 24 months. TLS/FUS-ERG chimeric mRNA was not detected after CR. This is the first report of an ALL patient with a TLS/FUS-ERG fusion transcript.
Kanazawa
Takashi
T
Department of Pediatrics and Developmental Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. tkanazaw@showa.gunma-u.ac.jp
Ogawa
Chitose
C
Taketani
Takeshi
T
Taki
Tomohiko
T
Hayashi
Yasuhide
Y
Morikawa
Akihiro
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001483:Base Sequence; D002874:Chromosome Mapping; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005091:Exons; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007223:Infant; D008297:Male; D018365:Neoplasm, Residual / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics*; D034702:RNA-Binding Protein FUS / Q000235:genetics*; D014178:Translocation, Genetic; D016896:Treatment Outcome
D015514:Oncogene Proteins, Fusion; D034702:RNA-Binding Protein FUS; C107302:TLS-ERG fusion protein, human; D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin